MedTrace Logo

Blister Packaging Medication to Increase Treatment Adherence and Clinical Response

NCT01118208 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2017-10-20

No results posted yet for this study

Summary

This quantitative, interview-based study will determine if increased prescription medication adherence via blister pack administration will reduce suicide related behavior among the high risk population of patients discharged from a psychiatric inpatient unit. The aims of the project are to determine whether blister packaging medication significantly increases treatment adherence and if blister packaging significantly decreases intentional self-poisoning behavior (i.e., suicide attempts and completions). By tracking former psychiatric inpatients for 12 months post-discharge and obtaining monthly medication adherence ratings, we will determine if blister packaging (BP) medications leads to better adherence than dispensing as usual (DUA). The psychiatric patients we will be recruiting have been diagnosed with, major affective disorder, bipolar affective disorder, post-traumatic stress disorder, or schizophrenia (or any combination of these diagnoses). By tracking former psychiatric patients for 12 months post-discharge and obtaining monthly reports (self-report and medical record review) of suicide-related behaviors, we will determine if patients in the BP condition have less intentional self-poisoning behavior than those in the DAU condition.

Conditions

  • Medication Adherence
  • Accidental Overdose
  • Deliberate Overdose
  • Suicide, Attempted

Interventions

OTHER

Blister packaging medications

Dispensing prescription medications on pre-filled blister package cards.

OTHER

Dispense as usual

Dispensing prescription medications in standard pill bottles.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • VA Eastern Colorado Health Care System

    lead FED

Principal Investigators

  • Peter M Gutierrez, Ph.D. · VA VISN 19 MIRECC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-06-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118208 on ClinicalTrials.gov